Technical Analysis for IKT - Inhibikase Therapeutics, Inc.

Grade Last Price % Change Price Change
D 2.01 -4.74% -0.10
IKT closed down 4.74 percent on Monday, March 18, 2024, on 54 percent of normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: Mar 29
*** please verify all earnings dates ***
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Fell Below 200 DMA Bearish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Stochastic Reached Oversold Weakness 0.00%
BB Squeeze + Lower Band Touch Range Contraction 0.00%
Gapped Up Strength 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakdown about 11 hours ago
Fell Below 200 DMA about 11 hours ago
200 DMA Support about 13 hours ago
Down 5% about 13 hours ago
Down 3% about 13 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Inhibikase Therapeutics, Inc. Description

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease, and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a c-Abl protein kinase inhibitor for use in the treatment of Parkinson's Disease, dysphagia, and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects. Its research phase products comprise IkT-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body; and IkT-148x series of portfolio compounds for use in the treatment of Dementia with Lewy Body and Multiple System Atrophy. The company was founded in 2008 and is headquartered in Atlanta, Georgia


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Medicine Parkinson's Disease Neurological Disorders Dementia Psychiatric Diagnosis Stage Pharmaceutical Treatment Of Parkinson's Disease Aging Associated Diseases Neurodegenerative Disorders Pyridines Lewy Body Dementia Imatinib Multiple System Atrophy

Is IKT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 4.9194
52 Week Low 0.79
Average Volume 165,902
200-Day Moving Average 2.03
50-Day Moving Average 2.26
20-Day Moving Average 2.25
10-Day Moving Average 2.29
Average True Range 0.23
RSI (14) 38.27
ADX 18.95
+DI 15.83
-DI 23.31
Chandelier Exit (Long, 3 ATRs) 1.92
Chandelier Exit (Short, 3 ATRs) 2.64
Upper Bollinger Bands 2.49
Lower Bollinger Band 2.01
Percent B (%b) 0.0
BandWidth 21.18
MACD Line -0.04
MACD Signal Line 0.00
MACD Histogram -0.0394
Fundamentals Value
Market Cap 12.43 Million
Num Shares 6.19 Million
EPS -3.99
Price-to-Earnings (P/E) Ratio -0.50
Price-to-Sales 49.63
Price-to-Book 1.13
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.33
Resistance 3 (R3) 2.34 2.26 2.27
Resistance 2 (R2) 2.26 2.18 2.25 2.25
Resistance 1 (R1) 2.13 2.13 2.09 2.12 2.24
Pivot Point 2.05 2.05 2.03 2.04 2.05
Support 1 (S1) 1.92 1.97 1.88 1.91 1.78
Support 2 (S2) 1.84 1.92 1.83 1.77
Support 3 (S3) 1.71 1.84 1.75
Support 4 (S4) 1.70